Track market-moving stories before they get noisy

Ocugen NASDAQ: OCGN outlined plans to advance three late-stage retinal disease programs, with company speaker Shankar saying the company is targeting biologics license applications for retinitis pigmentosa and Stargardt disease next year and a third BLA for geographic atrophy in 2028.

Speaking during a Piper Sandler discussion with analyst Biren Amin, Shankar said Ocugen is focused on inherited retinal diseases and dry age-related macular degeneration, including retinitis pigmentosa, Stargardt disease and geographic atrophy, the late form of dry AMD. He cited more than 100,000 retinitis pigmentosa patients in the U.S., about 50,000 Stargardt disease patients in the U.S. and 2 million to 3 million geographic atrophy patients in the U.S. and EU in the late stage of disease.

Get Ocugen alerts:

Shankar said Ocugen has retinitis pigmentosa and Stargardt programs in Phase 3 and expects to begin a global Phase 3 program for geographic atrophy in the third quarter, with alignment from regulators in the U.S. and Europe.

OCU410 Phase 3 Plans for Geographic Atrophy Amin began by asking about OCU410, Ocugen’s gene therapy candidate for geographic atrophy. Shankar said the therapy uses a modified RORA gene, which Ocugen is also using in its Stargardt program. He said RORA is intended to regulate multiple pathways involved in disease progression, including oxidative stress, lipid metabolism, inflammation and the complement system.

Shankar contrasted the approach with currently approved therapies that target the complement system, saying Ocugen believes RORA could help “reset” cellular homeostasis and create a healthier environment for photoreceptors and retinal pigment epithelial cells. He said Phase 2 data showed treatment benefit in one year, while many trials in the disease area run for at least two years.

Discussing Phase 2 results, Shankar said the medium dose showed about a 33% reduction in lesion growth when using the square root measure, while the company observed a bell-shaped dose-response pattern rather than a linear one. He said the high dose did not perform as consistently as the medium dose, leading Ocugen to select the medium dose for Phase 3.

For the pivotal study, Shankar said Ocugen plans to use a baseline lesion size range of 2.5 mm squared to 17.5 mm squared, consistent with approved products, and will measure the rate of change in lesion size at four-month intervals through 12 months. He said the company expects to enroll fewer than 300 patients and plans an adaptive design in which a data monitoring committee may review the trial after 50% of patients complete one year.

Shankar said Ocugen designed the trial assuming an effect size lower than the Phase 2 result, using roughly 25% to build in a buffer. Secondary endpoints will include ellipsoid zone preservation and low-luminance visual acuity. He said the medium dose showed about 27% preservation of ellipsoid zone loss in Phase 2, and the company hopes to see results in the 20%-plus range.

On safety, Shankar said there were no serious adverse events related to the drug in Phase 2, though some surgery-related issues can occur with vitrectomy and most resolved.

Stargardt Program OCU410ST Amin also asked about OCU410ST, Ocugen’s program for Stargardt disease. Shankar said Phase 1 results from the GARDian1 trial showed a 54% reduction in lesion growth in evaluable subjects compared with untreated eyes, using the contralateral eye as a control. He said the result informed the design of the Phase 2/3 pivotal study, which included 51 planned subjects, with 34 treated and 17 untreated.

Shankar said the company is also monitoring ellipsoid zone and low-luminance visual acuity as secondary measures. He said the program is intended as a one-time therapy and is being studied across a broad range of patients, including pediatric and adult patients aged three and older and patients from early to advanced stages of disease.

The GARDian3 pivotal trial includes an adaptive sample size re-estimation, which Shankar said is expected this quarter. He said the data monitoring committee could recommend no change, an adjustment in sample size or an extension of follow-up from 12 months to 16 months. Ocugen over-recruited the study to 63 patients, he said, potentially reducing the need for additional enrollment if the committee recommends a larger sample.

If no changes are made, Shankar said top-line results are expected in the second quarter of next year, followed by a BLA filing “a few weeks after that” or around mid-next year. If the timeline is extended, he said any delay could be roughly four to six months and still could allow the company to reach year-end next year. He also said no serious adverse events related to the drug have been observed so far in the Stargardt program.

OCU400 for Retinitis Pigmentosa Ocugen’s third program, OCU400, targets retinitis pigmentosa. Shankar said enrollment is complete in the Phase 3 trial, with top-line data expected in the first half of next year. He described the trial as a large genetic medicine study with 140 patients and more than 25 genetic mutations represented.

Shankar said OCU400 uses NR2E3 delivered through an AAV vector and is designed to be gene-agnostic by upregulating key transcription factors and helping reset cellular function. He said the trial includes a 2:1 randomization ratio, with more patients in the treatment arm than the control arm, and covers a broad population that includes syndromic and non-syndromic retinitis pigmentosa.

The primary functional assessment will use a Luminance Dependent Navigation Assessment, which Shankar said is similar to the multi-luminance mobility test used in the approval of Luxturna but modified to be more specific and sensitive. He said the trial will compare the rate of improvement over one year against the control arm.

Upcoming Milestones Shankar said Ocugen is aiming for two top-line readouts next year from its retinitis pigmentosa and Stargardt programs, followed by a third program readout in geographic atrophy in 2028. He reiterated the company’s goal of filing three BLAs over the next two years, followed by marketing authorization applications and potential global approvals.

“We’re going after with our one-time potential treatments, targeting hundreds of thousands to millions,” Shankar said, describing that as a key point of differentiation for the company.

About Ocugen NASDAQ: OCGNOcugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Ocugen Right Now?Before you consider Ocugen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocugen wasn't on the list.

While Ocugen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Key Takeaways OCGN targets Q3 2026 rolling BLA for OCU400, with top-line Phase III data expected in Q1 2027.OCU410ST completed pivotal enrollment and dosing; interim data are due Q3 2026, top-line in Q2 2027.OCU410 plans a Phase III start in Q3 2026 after Phase II lesion-growth reduction signals and clean safety. Ocugen (OCGN - Free Report) is advancing three one-time gene therapy programs for retinal diseases, each aimed at conditions with large unmet needs and limited effective options.

The company’s late-stage calendar clusters multiple clinical readouts and regulatory steps into 2026 and 2027, setting up a dense catalyst window for a stock that can swing sharply on data and policy decisions.

OCGN’s 2026-27 Calendar in One ViewOcugen frames 2026 as pivotal because it expects meaningful milestones across all three core ocular programs in the same year. The cadence includes regulatory progress for the lead candidate and an interim clinical update for a second pivotal study, while a third program is positioned to enter Phase III.

That synchronization matters because it concentrates investor attention on a short list of binary events, rather than a long, diffuse development timeline. At the same time, the setup carries risk because the company has no approved products, burns cash, and remains dependent on high-risk trials and regulatory outcomes.

The first quarter of 2027 matters most for OCGN because it is the expected window for top-line Phase III results for the lead program. That readout sits directly on top of the company’s planned regulatory path and is the clearest single event in the stated 2026-27 timeline.

Ocugen’s Lead Programs and What They TreatOcugen’s three core retinal targets are retinitis pigmentosa, Stargardt disease, and geographic atrophy, each associated with progressive vision loss and limited treatment choices today. The company positions these programs around large underserved populations and a lack of effective options, particularly for Stargardt disease and geographic atrophy in Europe.

For retinitis pigmentosa, the company highlights broad genetic complexity, with mutations across more than 100 genes. It also points to the narrow reach of the only approved gene therapy approach cited, which targets a small fraction of the population.

For Stargardt disease, the emphasis is on the absence of approved options and a mutation profile that is wide enough to support a “one-time” approach that aims to address many disease-causing variants. For geographic atrophy, the company contrasts the burden of repeated injections in existing U.S. treatment with the goal of a one-time therapy that addresses multiple aspects of disease biology.

OCGN and OCU400: What Comes FirstOCU400 is Ocugen’s lead modifier gene therapy program for retinitis pigmentosa, and enrollment is complete in the Phase III liMeliGhT study, which enrolled 140 patients.

The next stated regulatory step is a rolling biologics license application targeted for the third quarter of 2026, positioning OCU400 toward a potential approval pathway in 2027 if the Phase III package supports it. The FDA has granted orphan drug designation for OCU400 in retinitis pigmentosa.

The company’s key clinical catalyst is top-line Phase III timing expected in the first quarter of 2027. Earlier studies are characterized as showing durable safety and meaningful vision improvement, which sets the baseline narrative going into the pivotal readout.

Ocugen and OCU410ST: Interim Data SetupOCU410ST is being developed as a one-time gene therapy for Stargardt disease, and enrollment and dosing have been completed in the Phase II/III GARDian3 pivotal confirmatory study.

The next milestones are staged: interim data are expected in the third quarter of 2026, followed by top-line results anticipated in the second quarter of 2027. That sequencing keeps Stargardt disease as a parallel catalyst stream alongside the OCU400 program.

Ocugen targets a mid-2027 biologics license application submission for OCU410ST. Earlier Phase I results are described as having the potential to provide clinically meaningful functional and structural benefits in Stargardt disease patients.

OCGN and OCU410: From Phase II Signal to Phase III StartOCU410 is being developed as a one-time gene therapy for geographic atrophy secondary to dry age-related macular degeneration. The Phase II efficacy narrative emphasizes the medium dose as the optimal dose intended for Phase III development.

Across Phase II updates, Ocugen cites lesion-growth reduction signals versus control, including a 31% reduction at 12 months for the medium dose and a 54% reduction versus control for the medium dose in a separate disclosure of 12-month performance. The company also points to a clean safety profile with no treatment-related serious adverse events across studies cited.

The next development step is the plan to begin a Phase III registrational study in the third quarter of 2026, moving geographic atrophy into the same late-stage rhythm as the other programs.

Ocugen’s “Three Filings by 2028” GoalOcugen’s stated strategy is to run these programs on synchronized tracks, with three regulatory applications planned over the next three years, turning a multi-asset pipeline into a rolling series of potential catalysts.

This setup can create multiple moments for the market to reassess OCGN, especially as 2026 brings a rolling filing for OCU400, interim Stargardt data, and a planned Phase III start in geographic atrophy, followed by pivotal readouts in 2027.

The flip side is that the same tight calendar can amplify volatility. For context, other gene-therapy-focused names like REGENXBIO (RGNX - Free Report) and MeiraGTx Holdings (MGTX - Free Report) also operate in an event-driven clinical landscape, where trial updates and regulatory signals can reshape expectations quickly. For OCGN, the ultimate direction still depends on clinical execution and regulatory outcomes over 2026 and 2027.

OCGN’s Zacks RankOcugen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here

Key Takeaways OCGN says OCU400 could address 98% to 99% of retinitis pigmentosa patients across mutations.OCU410ST targets Stargardt disease with interim data due Q3 2026 and top-line results in Q2 2027.OCU410 plans Phase III in Q3 2026 after Phase II lesion-growth reduction signals in geographic atrophy. Ocugen (OCGN - Free Report) is pushing a modifier gene therapy platform across several retinal diseases where current options are limited, burdensome, or simply absent. The common thread is a “gene-agnostic” concept that aims to help broad patient groups with one-time treatment rather than chasing single mutations one by one.

With multiple late-stage timelines converging and several 2026 readouts and regulatory steps on the calendar, the setup is increasingly catalyst-driven. At the same time, Ocugen has no approved products and continues to burn cash, keeping risk elevated.

OCGN’s Modifier Gene Therapy Explained SimplyInherited retinal diseases like retinitis pigmentosa can be caused by many different genetic mutations. Ocugen’s modifier gene therapy platform is designed to work across mutations, rather than matching a therapy to a single defective gene.

That stands apart from a mutation-specific paradigm, where treatment eligibility can narrow sharply depending on the patient’s exact gene defect. In practice, Ocugen is trying to make one therapy relevant to many genetic subtypes, which could expand both clinical utility and commercial reach if efficacy and safety hold up in late-stage testing.

Ocugen’s “Broad Coverage” Claim in RPRetinitis pigmentosa is associated with mutations in more than 100 genes, creating a fragmented landscape for drug development. The company’s framing highlights that there is only one approved gene therapy for retinitis pigmentosa, and it targets a single mutation representing about 1% to 2% of the total retinitis pigmentosa population.

OCU400 is positioned as a one-time subretinal injection that could treat multiple gene mutations, with the potential to cover about 98% to 99% of all retinitis pigmentosa patients. Enrollment is complete in the Phase III liMeliGhT study, and top-line data is expected in the first quarter of 2027. The company expects to begin filing a rolling biologics license application in the third quarter of 2026, supported by ongoing Chemistry Manufacturing and Controls work. The Food and Drug Administration has also granted orphan drug designation to OCU400 for retinitis pigmentosa.

OCGN’s One-Time Approach in Stargardt DiseaseOCU410ST is being developed as a one-time gene therapy for Stargardt disease, a condition with no Food and Drug Administration-approved treatments. That lack of approved options is a key reason the upcoming clinical updates carry high attention potential.

Ocugen’s patient population framing emphasizes scale and genetic complexity. Stargardt disease affects roughly 100,000 patients in the United States and the European Union and about 1 million globally. OCU410ST is positioned to address more than 1,200 disease-causing mutations in the ABCA4 gene with a single therapy, including ABCA4-related retinopathies. Enrollment and dosing have been completed in the Phase II/III GARDian3 pivotal confirmatory study, with interim data expected in the third quarter of 2026 and top-line data anticipated in the second quarter of 2027. A biologics license application submission is targeted for mid-2027.

Ocugen’s GA Thesis Beyond Anti-ComplementGeographic atrophy is another area where Ocugen is arguing for a shift in the treatment paradigm. The company notes that current options can require multiple injections and focus on one aspect of disease, while OCU410 is intended as a one-time gene therapy that addresses multiple aspects beyond the complement pathway.

In Phase II, preliminary signals highlighted lesion growth reduction at 12 months. The company has described a 46% lesion growth reduction across the medium- and high-dose groups versus control, with the medium dose showing the strongest effect. A later 12-month update described a 31% reduction versus control at the medium dose and reiterated that the medium dose is intended for Phase III development. Phase III is planned to begin in the third quarter of 2026.

This is also where comparisons naturally arise to companies building around complement inhibition. Apellis Pharmaceuticals , for example, remains a closely watched name in geographic atrophy, and it currently carries a Zacks Rank #3 (Hold).

OCGN’s De-Risking Attempts Through PartnershipsWith no marketed products, Ocugen’s strategy includes monetizing select geographies while keeping broader upside. In 2025, the company signed its first licensing agreement with Kwangdong Pharmaceutical for exclusive South Korea rights to OCU400, explicitly framed as regional monetization without giving up global opportunity.

Collaborative revenue is expected to come from licensing, milestones, royalties, and supply. Fiscal 2025 revenue totaled $4.4 million, driven primarily by the CanSinoBIO co-development and commercialization agreement, while no revenue was recognized under the Kwangdong OCU400 agreement in 2025 because there was no product delivery during the period.

Ocugen’s Platform Optionality Beyond OphthalmologyBeyond the lead ocular gene therapy programs, Ocugen has several programs that can diversify risk but remain early or execution-dependent. OCU200 is a novel biologic in Phase I for retinal vascular diseases, and the company has navigated prior regulatory delays that pushed timelines out before the program moved forward.

NeoCart is described as a Phase III-ready regenerative cell therapy for knee cartilage repair, adding a non-ophthalmology asset with nearer-term development readiness. The inhaled mucosal vaccine platform, including OCU500, OCU510 and OCU520, broadens exposure to infectious diseases and has external support, including National Institute of Allergy and Infectious Diseases backing for planned Phase I initiation.

Investors weighing platform optionality often benchmark against other gene-therapy-focused developers. Sarepta Therapeutics (SRPT - Free Report) , a prominent name in genetic medicine, currently carries a Zacks Rank #3 (Hold).

OCGN's Zacks RankOcugen currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 5, 2026.

MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ocugen also granted the initial purchaser of the notes a 13-day option to purchase up to an additional $15 million aggregate principal amount of the notes. The sale of the notes to the initial purchaser is expected to close on May 7, 2026, subject to customary closing conditions, and is expected to result in approximately $99.5 million (or approximately $112.6 million if the initial purchaser exercises its option to purchase additional notes in full) in net proceeds to Ocugen after deducting the initial purchaser’s discount and estimated offering expenses payable by Ocugen.

The offering price of the notes is 90% of the principal amount of notes. Ocugen intends to use approximately $32.7 million of the net proceeds from the offering to fully repay the outstanding principal amount of, plus accrued and unpaid interest on, the loan outstanding under its Loan and Security Agreement with affiliates of Avenue Capital Group (the “Avenue Loan Agreement”), and pay the related prepayment fee and other fees and expenses in connection therewith. Ocugen expects to use the remaining net proceeds from the offering, including any additional proceeds from the initial purchaser’s exercise of its option to purchase additional notes, for general corporate purposes.

The notes will be Ocugen’s general unsecured obligations and will rank senior in right of payment to all of its future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to all of its existing and future liabilities that are not so subordinated, and junior to all of its secured indebtedness, to the extent of the value of the assets securing such indebtedness. Interest will be payable semi-annually in arrears. The notes will bear interest at a rate of 6.75% per year. Interest will be payable semi-annually in arrears on May 15 and November 15 of each year, beginning on November 15, 2026. The notes will mature on May 15, 2034, unless earlier repurchased, redeemed or converted.

Ocugen may not redeem the notes prior to May 15, 2029. Ocugen may redeem for cash all or any portion of the notes (subject to certain limitations), at its option, on or after May 15, 2029 and prior to the 41st scheduled trading day immediately preceding the maturity date, if the last reported sale price of Ocugen’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which Ocugen provides notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. Holders of the notes may require Ocugen to repurchase for cash all or any portion of their notes on May 15, 2032 at a repurchase price equal to 100% of the principal amount of notes to be repurchased, plus accrued and unpaid interest to, but excluding May 15, 2032. In addition, holders of the notes will have the right to require Ocugen to repurchase all or a portion of their notes upon the occurrence of a fundamental change (as defined in the indenture governing the notes) at a purchase price of 100% of their principal amount plus any accrued and unpaid interest to, but excluding, the relevant fundamental change repurchase date.

The notes may not be converted prior to the earlier of (i) May 15, 2027 and (ii) the “reserved share effective date” (as defined in the indenture governing the notes), which is effectively the date on which Ocugen reserves the maximum number of shares of common stock underlying the notes. The notes will be convertible at an initial conversion rate of 372.7866 shares of Ocugen’s common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $2.68 per share, which represents a conversion premium of approximately 45% to the last reported sale price of $1.85 per share of Ocugen’s common stock on The Nasdaq Capital Market on May 4, 2026). Conversions of the notes may be settled in cash, shares of Ocugen’s common stock, or a combination thereof, at Ocugen’s election; provided that unless and until the reserved share effective date occurs, conversions of the notes will be settled via cash settlement.

The notes were only offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act. Neither the notes nor the shares of Ocugen’s common stock potentially issuable upon conversion of the notes, if any, have been, or will be, registered under the Securities Act or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States except pursuant to an applicable exemption from such registration requirements.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including but not limited to, statements regarding the anticipated use of proceeds from the offering, including the repayment of the Avenue Loan Agreement; the completion of the offering, and other statements contained in this press release that are not historical facts. Ocugen may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from Ocugen’s current expectations, including, but not limited to: risks related to the offering and uncertainties related to market conditions; the impact of the offering on the market price of Ocugen’s common stock; and risks related to the potential dilution to holders of Ocugen’s common stock. These and other risks and uncertainties are more fully described in Ocugen’s periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that Ocugen files with the SEC. Any forward-looking statements that Ocugen makes in this press release speak only as of the date of this press release. Except as required by law, Ocugen assumes no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:

Candice Masse
astr partners
[email protected]

Ocugen (OCGN - Free Report) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -12.57%. A quarter ago, it was expected that this biotech knee implant developer would post a loss of $0.06 per share when it actually produced a loss of $0.06, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Ocugen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.53 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 27.75%. This compares to year-ago revenues of $1.48 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Ocugen shares have added about 37% since the beginning of the year versus the S&P 500's gain of 5.2%.

What's Next for Ocugen?While Ocugen has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Ocugen was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.05 on $1.2 million in revenues for the coming quarter and -$0.22 on $5.4 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Sutro Biopharma, Inc. (STRO - Free Report) , has yet to report results for the quarter ended March 2026.

This company is expected to post quarterly loss of $2.32 per share in its upcoming report, which represents a year-over-year change of +74.5%. The consensus EPS estimate for the quarter has been revised 14.9% higher over the last 30 days to the current level.

Sutro Biopharma, Inc.'s revenues are expected to be $8.96 million, down 48.5% from the year-ago quarter.

Key Takeaways OCGN posted a Q1 loss of 6 cents per share, wider than estimates and the prior-year loss.Ocugen's expenses rose on accelerated R&D and commercial preparation, lifting operating costs.OCGN advanced gene therapy pipeline, reporting strong OCU410 data and achieving key trial milestones. Ocugen (OCGN - Free Report) incurred a loss of 6 cents per share in the first quarter of 2026, wider than the Zacks Consensus Estimate as well as the year-ago loss of 5 cents.

Ocugen’s total revenues rose 3.5% year over year to $1.5 million in the first quarter, beating the Zacks Consensus Estimate of $1 million.

The company’s top line currently comprises only collaboration revenues.

OCGN’s Q1 Results in DetailOcugen’s operating expenses increased during the quarter as the company accelerated clinical development and commercial preparation activities.

Research and development expenses were $11.3 million, up 18.1% from the year-ago quarter’s level. General and administrative expenses totaled $8.1 million, up 25.8% year over year.

As of March 31, 2026, Ocugen had cash, cash equivalents and restricted cash worth $32.2 million compared with $18.9 million as of Dec. 31, 2025. Management stated that the company expects its recent $115 million convertible senior notes offering to extend the cash runway into 2028.

OCGN’s Pipeline Progress & Clinical UpdatesOcugen continued to make significant progress across its ophthalmology gene therapy portfolio during the quarter, with management targeting three biologics license application (BLA) submissions by 2028.

In March, the company completed patient enrollment in the phase III liMeliGhT registrational study on OCU400 for the treatment of patients with retinitis pigmentosa, a rare genetic disorder that can lead to vision loss and blindness. Top-line data is expected in the first quarter of 2027. OCGN plans to begin a rolling BLA submission in the third quarter of 2026 and complete it by the second quarter of 2027. Potential FDA approval is anticipated in the fourth quarter of 2027.

Ocugen also achieved an important milestone for another gene therapy candidate, OCU410ST. In April, the company completed enrollment and dosing in the phase II/III GARDian3 pivotal confirmatory study evaluating OCU410ST for the treatment of Stargardt disease, a rare inherited retinal disorder with no approved treatments currently available. The milestone was achieved ahead of schedule.

Top-line data is anticipated in the second quarter of 2027. The company targets a mid-2027 BLA submission for OCU410ST.

One of the quarter’s most important developments was positive 12-month top-line data from the phase II ArMaDa study evaluating OCU410 in geographic atrophy secondary to dry age-related macular degeneration.

The therapy achieved a statistically significant 31% reduction in lesion growth at the optimal (medium) dose compared with the control group and showed approximately 27% slower rate of ellipsoid zone loss, a key indicator linked to visual function. Around 20% of treated patients experienced no disease progression, while nearly 75% achieved more than a 30% reduction in lesion growth.

Based on the data, OCGN plans to initiate a phase III registrational study in the third quarter of 2026 with potential BLA filing by 2028.

Shares of OCGN fell sharply by around 19% on Tuesday despite key timelines for its pipeline candidates being maintained. The decline could be because investors focused more on the company’s rising costs and operating losses along with the earnings release. Ocugen recently announced and priced a $115 million private offering of 6.75% convertible senior notes due 2034, with an option to raise an additional $15 million. This may have weighed on investor sentiment as the potential increase to $130 million raised concerns about dilution and higher future debt obligation.

Year to date, shares of OCGN have risen 10.4% against the industry’s 2.4% decline.

Image Source: Zacks Investment Research

OCGN's Zacks Rank & Stocks to ConsiderOcugen currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Castle Biosciences (CSTL - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy) and Catalyst Pharmaceuticals (CPRX - Free Report) , which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.42 to $1.40. Over the same period, loss per share estimates for 2027 have also narrowed from 79 cents to 78 cents. CSTL shares have lost 36.7% year to date.

Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 34.69%.

Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.03 to $3.26. Over the same period, EPS estimates for 2027 have risen from $3.40 to $3.57. INDV shares have risen 10.3% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have declined from $2.82 to $2.79. Over the same period, EPS estimates for 2027 have surged from $3.20 to $3.28. CPRX shares have gained 32.3% year to date.

Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.

May 13, 2026 07:02 ET  | Source: Ocugen

MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific and investor conferences in May 2026.

Retina World Congress

Inherited and Rare Retinal Diseases Session
Moderators: Kourous A. Rezaei, MD and Rishi P. Singh, MD, FASRS
Location: Grand Ballroom
Date: Thursday, May 14, 2026
Time: 10:31 am – 11:10 a.m. EDT

Stifel 2026 Virtual Ophthalmology Forum

Location: Virtual
Date: Tuesday, May 26, 2026
Time: 10:30 am – 10:55 a.m. EDT

A webcast of the Stifel presentation will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit Investors | Ocugen, Inc.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Investor Contact:
Candice Masse
astr partners
[email protected]

June 02, 2026 07:03 ET  | Source: Ocugen

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in June 2026.

Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference

Date: Thursday, June 4, 2026
Time: 2:30pm EDT

Clinical Trials at the Summit 2026

Location: Fontainebleau Las Vegas
Date: Saturday, June 13, 2026
Time: 10:19 – 10:39 am PDT
Inherited Retinal Diseases: Transforming the Future Through Innovation
Moderator: Peter Kaiser
Panelists: Lance Baldo, Paul Bresge, Eliot Lazar, George Magrath, Nathan Mata, Shankar Musunuri, Jayashree Sahni

BIO International Convention

Location: Theater 3
Date: Tuesday, June 23, 2026
Time: 11:00 am PDT

A webcast of the Noble presentation will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit Investors | Ocugen, Inc.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Investor Contact:
Candice Masse
astr partners
[email protected]

Key Takeaways OCGN expects key OCU400 and OCU410ST data in 2027, with filings targeted through 2028.OCGN raised capital and says its May 2026 financing extends cash runway into 2028.OCGN has no approved products and faces dilution, cash burn, and regulatory execution risks. Ocugen (OCGN - Free Report) is pushing three eye gene therapy programs toward late-stage regulatory timelines, setting up a catalyst-heavy stretch in 2026 and 2027. That opportunity comes with familiar biotech trade-offs. The company has no approved products, spends heavily to move trials forward, and has leaned on capital markets to extend its runway. The key question is whether upcoming clinical milestones justify the dilution and execution risk.

OCGN Q1 2026 Loss, Sales, and Expense TrendsOcugen posted a first-quarter 2026 loss of 6 cents per share, wider than both the year-ago loss of 5 cents per share and the Zacks Consensus Estimate.

Revenue was a bright spot. Total revenue rose 3.5% year over year to $1.5 million, beating the Zacks Consensus Estimate of $1.0 million, with the current top line driven by collaboration revenue.

Operating costs moved higher as the company accelerated clinical development and commercial preparation. Research and development expense was $11.3 million, up 18.1% year over year, while general and administrative expense totaled $8.1 million, up 25.8%.

Ocugen’s Cash Position and Why Dilution Still MattersCash burn remains a central risk variable. First-quarter 2026 operating cash use was $21.8 million, underscoring the pressure to keep funding the pipeline while trials and filings ramp.

Ocugen bolstered liquidity through multiple actions. In the first quarter, it raised $37.5 million in gross proceeds, including $22.5 million from a registered direct offering and $15.0 million from warrant exercises. Cash, cash equivalents, and restricted cash increased to $32.2 million as of March 31, 2026, up from $18.9 million at the end of 2025.

The bigger step came in May 2026, when Ocugen completed a convertible senior notes financing that raised $130 million after the full exercise of an overallotment option, with net proceeds of about $112.6 million. The company used a portion of the proceeds to fully repay its Avenue Capital loan and related obligations, and management said the financing extends the cash runway into 2028.

OCGN Gene Therapy Upside Into 2027 and BeyondOcugen’s upside case is built around a synchronized sequence of late-stage milestones across three ocular programs. Enrollment is complete in the phase III liMeliGhT study for OCU400 in retinitis pigmentosa, with top-line data expected in the first quarter of 2027.

On the Stargardt disease program, OCU410ST has completed enrollment and dosing in the phase II/III GARDian3 pivotal confirmatory study. Ocugen expects interim data in the third quarter of 2026 and top-line data in the second quarter of 2027, with a biologics license application filing planned for mid-2027.

For geographic atrophy, Ocugen plans to initiate a registrational phase III study of OCU410 in the third quarter of 2026. That keeps the company aligned with its goal of filing three biologics license applications by 2028.

Ocugen’s GA Data Versus Current Options in Dry AMDIn geographic atrophy secondary to dry age-related macular degeneration, Ocugen’s phase II ArMaDa readout supports its dose strategy heading into the planned registrational study. At 12 months, the intended medium dose produced a statistically significant 31% reduction in lesion growth versus control, along with 27% ellipsoid zone preservation.

Earlier 12-month data also pointed to a stronger signal: a 46% lesion growth reduction across the medium- and high-dose groups, and a 54% lesion reduction for the medium dose versus control.

Dose selection matters because the phase III design will likely lean on the dose that best balances efficacy and consistency. Ocugen has identified the medium dose as the optimal dose intended for phase III development, which is a key execution point as the program moves from signal generation to a registrational setting.

For context, today’s approved geographic atrophy therapies include Syfovre from Apellis Pharmaceuticals, which was recently acquired by Biogen (BIIB - Free Report)  and Izervay from Astellas Pharma (ALPMY - Free Report) , both approved in 2023, and both delivered via repeated intravitreal injections.

OCGN Valuation Multiples and What Investors Are Pricing InOcugen trades at a premium sales multiple that reflects high optionality. The shares are valued at 46.05X forward 12-month sales per share, versus 1.96X for the Zacks sub-industry, 2.13X for the Zacks sector, and 5.27X for the S&P 500.

That premium also needs to be framed against volatility. Over the past five years, the stock has traded as high as 501.84X and as low as 2.08X, with a five-year median of 73.70X.

Performance metrics reinforce the same message. The shares were down 0.7% year to date but up 51% over the past year, signaling that investors are already discounting the possibility of meaningful inflection points around 2027 and 2028 milestones.

Ocugen Decision Checklist for Risk-Tolerant InvestorsThe clearest “green lights” are operational. Ocugen has late-stage alignment across OCU400, OCU410ST, and OCU410, with planned phase III execution and filings that support the stated goal of three biologics license applications by 2028, alongside management’s stated runway extension into 2028.

The “red flags” are equally direct. The company has no approved products, revenue is currently collaboration-driven, cash burn is heavy, and the capital structure now includes convertible notes that can create dilution risk if converted, alongside added leverage. Past regulatory delays, such as the earlier clinical hold on OCU200, also show how timelines can slip.

A milestone-based approach fits this setup. In 2026, investors can watch for the planned phase III start for OCU410 in the third quarter, the OCU400 rolling biologics license application timing in the third quarter, and interim data for OCU410ST in the third quarter. In 2027, the most important swing factors are top-line data from OCU400 in the first quarter and OCU410ST in the second quarter.

OCGN’s Zacks RankOcugen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

A month has gone by since the last earnings report for Ocugen (OCGN - Free Report) . Shares have lost about 10.7% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Ocugen due for a breakout? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for Ocugen, Inc. before we dive into how investors and analysts have reacted as of late.

Q1 Loss Wider Than Expected, Sales Beat EstimatesOcugen incurred a loss of 6 cents per share in the first quarter of 2026, wider than the Zacks Consensus Estimate as well as the year-ago loss of 5 cents.

Ocugen’s total revenues rose 3.5% year over year to $1.5 million in the first quarter, beating the Zacks Consensus Estimate of $1 million.

The company’s top line currently comprises only collaboration revenues

Q1 Results in DetailOcugen’s operating expenses increased during the quarter as the company accelerated clinical development and commercial preparation activities.

Research and development expenses were $11.3 million, up 18.1% from the year-ago quarter’s level. General and administrative expenses totaled $8.1 million, up 25.8% year over year.

The company raised $37.5 million in gross proceeds during the first quarter of 2026, including $15 million from investors exercising their warrants. As a result, its cash, cash equivalents, and restricted cash increased to $32.2 million as of March 31, 2026, up from $18.9 million at the end of 2025.

Following the $115 million offering of convertible senior notes, the company expects to have approximately $112.1 million in cash, cash equivalents, and restricted cash when the transaction closes, which includes the Avenue debt payoff.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a upward trend in fresh estimates.

The consensus estimate has shifted 6.25% due to these changes.

VGM ScoresAt this time, Ocugen has a subpar Growth Score of D, a score with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a score of F on the value side, putting it in the fifth quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Ocugen has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerOcugen is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Axsome Therapeutics (AXSM - Free Report) , a stock from the same industry, has gained 4.9%. The company reported its results for the quarter ended March 2026 more than a month ago.

Axsome reported revenues of $191.2 million in the last reported quarter, representing a year-over-year change of +57.4%. EPS of -$1.26 for the same period compares with -$0.80 a year ago.

Axsome is expected to post a loss of $0.83 per share for the current quarter, representing a year-over-year change of +9.8%. Over the last 30 days, the Zacks Consensus Estimate has changed -15.5%.

Axsome has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.